Popular Sirolimus News and Current Events

Popular Sirolimus News and Current Events, Sirolimus News Articles.
Sort By: Most Relevant | Most Recent
Page 1 of 4 | 145 Results
Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression
A new immunosuppression regimen for heart transplant patients can improve kidney function and prevent transplant coronary artery disease, according to two new Mayo Clinic studies. Mayo researchers will report their findings on April 26 at the International Society for Heart & Lung Transplantation Annual Meeting and Scientific Session in San Francisco. (2007-04-26)

Potential cognitive effects of targeted drugs in children may be reversible with therapy
Young mice that received molecularly targeted therapies used to treat brain cancer in human patients sustained cognitive and behavioral deficits, but the deficits were largely reversible through environmental stimulation and physical exercise. The study suggests that pediatric brain cancer patients may experience similar side effects of molecularly targeted therapies, and may benefit from efforts to remediate any cognitive deficits. (2018-03-20)

IDIBELL researchers successfully test a new combination therapy in sarcomas
Researchers of the Sarcoma group of the Oncobell program -- Bellvitge Biomedical Research Institute (IDIBELL) have successfully tested a new combined therapy for the treatment of this rare, aggressive tumor type, which affects children and adults. (2018-01-16)

Transplant drug sirolimus shrinks tumors, improves lung function
The drug sirolimus, normally used to help transplant patients fight organ rejection, may eventually be used as a less invasive treatment for a tumor called angiomyolipomata in patients with tuberous sclerosis complex or lymphangioleiomyomatosis who would otherwise face surgery. The finding is reported by investigators from Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine in the Jan. 10 edition of the New England Journal of Medicine. (2008-01-09)

Grapefruit juice lets patients take lower dose of cancer drug
A glass a day of grapefruit juice lets patients derive the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself. The combination could help patients avoid side effects associated with high doses of the drug and reduce the cost of the medication. (2012-08-07)

The Lancet journals: Papers at ESC Congress 2019
The following papers will be presented at the ESC Congress 2019, organised by the European Society of Cardiology in Paris and published simultaneously in either The Lancet or The Lancet Global Health journals. All papers are under embargo until the stated time. Contact details for corresponding authors are provided in the Articles and linked Comments. Funding information is listed on the first page of each Article. (2019-09-03)

Northwell Health's Feinstein Institute discovers cancer treatment for transplant patients
Kenar D. Jhaveri, M.D., and Richard Barnett, M.D., Feinstein Institute for Medical Research scientists and Northwell Health Department of Internal Medicine nephrologists, published a Letter to the Editor in the prestigious New England Journal of Medicine, which profiles a novel drug combination with the potential to help prevent rejection of a donor kidney in transplant patients undergoing cancer treatment. (2017-01-18)

New guidelines issued for diagnosis and care of LAM, a rare lung disease
The American Thoracic Society (ATS) and the Japanese Respiratory Society (JRS) have published additional clinical practice guidelines regarding four specific questions related to the diagnosis of lymphangioleiomyomatosis (LAM) and management of pneumothoraces in patients with LAM. (2017-11-15)

Common cause for complications after kidney transplantation identified
The BK polyomavirus often causes complications after kidney transplantation. The research group of Professor Hans H. Hirsch from the Department of Biomedicine at the University of Basel has now been able to show, that the immunosuppressive drug Tacrolimus directly activates the replication of the virus and could thus be responsible for these complications. The American Journal of Transplantation has published the study. (2015-11-23)

Genetic breakthrough offers promise in tackling kidney tumors
Early tests show promising results for a new treatment for tuberous sclerosis, which can cause tumors in organs throughout the body. The UK study is led by Cardiff University's Institute of Medical Genetics, which was the first to identify the genes linked to the disease. (2008-01-10)

ACTG presents new research on HIV and TB, co-morbidities, treatment, and cure at CROI 2019
The AIDS Clinical Trials Group (ACTG), the world's largest and longest-established HIV research network, funded by NIAID at the U.S. NIH, will make 11 oral and 19 poster presentations at CROI 2019 (Seattle, March 4-7). Several have the potential to influence clinical practice and guidelines for care. (2019-02-26)

Cardiac stent patients with diabetes may benefit from drug that counteracts the effects of leptin
The naturally high levels of leptin in diabetic patients may reduce the effectiveness of drug-eluting stents used to treat heart blockages, but using a chemical that differs from the one commonly used to coat stents could counteract this effect. Work at Columbia University Medical Center could potentially improve outcomes in diabetics who get stents. Though drug-eluting stents reduce the chance coronary arteries will become blocked again, clogged stents are still more common in diabetic patients than in the general population. (2008-12-17)

Four-year data suggest the CYPHER® stent provides long-term efficacy and safety benefits
Patients treated with the CYPHER® Sirolimus-eluting Coronary Stent continued to experience significantly better long-term clinical outcomes than those who received a bare metal stent (BMS), according to data presented today during a symposium at the 2006 American College of Cardiology Scientific Session. (2006-03-13)

Study highlights benefits of drug-eluting stents in coronary revascularisation
A pooled analysis of 11 previously published trials provides evidence that drug-eluting stents (DES)--increasingly used in coronary angioplasty--have benefits over bare-metal stents (BMS) by reducing the need for later revascularisation and reducing the risk of cardiac events. However the study did not find that the use of DES reduced the risk of death or heart attack compared with BMS. (2004-08-12)

Versatile immunosuppressant drug may have new role in radiotherapy for cancer
The versatile immunosuppressant drug rapamycin may have yet another role - boosting the effectiveness of radiotherapy in cancer patients, a US doctor tells a joint European-US cancer conference in Frankfurt on Thursday 21 November. (2002-11-21)

European study initiated to compare sirolimus-eluting stenting vs. balloon angioplasty
Cordis Corp. will compare its Cypher Select + (Plus) sirolimus-eluting stent with balloon angioplasty, the company announced today at the EuroPCR meeting in Barcelona. The multicenter, prospective, randomized ACHILLES study will evaluate the performance of stenting vs. balloon angioplasty in patients with below-the-knee (infrapopliteal) peripheral artery disease. (2008-05-14)

Study shows low rate of late lumen loss with bioresorbable DESolve device
The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013 today. (2013-05-21)

Oncotarget: Sirolimus-eluting stents -- opposite in vitro effects on the clonogenic cell potential
The cover for issue 31 of Oncotarget features Figure 4, ''Concentration dose-response curves of sirolimus effect [55 nM-1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure,'' by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival. (2020-10-21)

CHOP experts describe research in pediatric heart disease
Physician-researchers from The Children's Hospital of Philadelphia presented new findings on pediatric cardiovascular disease at the American Heart Association's Scientific Sessions. They described racial disparities in risk factors for sudden cardiac death, imaging modalities and novel approaches to assessing cardiac anomalies, ventricular assist device use, changes in immunosuppressive drugs after pediatric heart transplant, and many other topics. (2012-11-08)

CYPHER® Sirolimus-eluting Coronary Stent benefits from clinical success, worldwide growth in 2005
New data from a Spanish study presented at the 2005 American Heart Association Scientific Sessions found that patients with bifurcation lesions fared significantly better when treated with the CYPHER® Sirolimus-eluting Coronary Stent compared with the Taxus stent in the areas of late loss, re-treatment (total lesion revascularization or TLR) and re-blockage (restenosis). This study was one of many clinical successes in 2005 for the CYPHER® Stent. (2005-12-21)

Researchers find drug-eluting stents safe, effective for PCI in diabetics
Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics scientific symposium, sponsored by the Cardiovascular Research Foundation. (2009-09-21)

Results from PRISON IV presented at TCT & published in JACC: Cardiovascular Interventions
Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin strut sirolimus-eluting stents (Osiro SES) with a biodegradable polymer compared to thin-strut everolimus-eluting stents (Xience EES) with a durable polymer in terms of in-segment late lumen loss in successfully treated chronic total occlusions. In addition, although the rate of binary restenosis was low overall in this complex lesion subset, it was higher with the Osirio SES compared with the Xience EES. (2016-11-07)

Grapefruit juice boosts drug's anti-cancer effects
Results from a small, early clinical trial show that combining grapefruit juice with the drug rapamycin can be effective in treating various types of cancer. The grapefruit juice increases drug levels, allowing lower doses of the drug to be given. (2009-04-20)

New therapies increase survival rates in post-transplant liver cancer patients
A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases. (2010-03-25)

CRF announces press conference schedule for TCT 2015
The Cardiovascular Research Foundation has announced the press conference schedule for late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics 2015 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place October 11-15, 2015 in San Francisco, California. (2015-09-22)

Results from REVELUTION reported at TCT & published in JACC: Cardiovascular Interventions
A first-in-human study of a new polymer-free drug-filled stent, which provides controlled drug elution from an internal lumen, indicated non-inferior in-stent late lumen loss at nine-months compared with historical zotarolimus-eluting stent (Resolute) data. In addition, there was no binary restenosis, and a high degree of early stent strut coverage with minimal malapposition. (2016-10-31)

Sirolimus-eluting Coronary Stent is cost effective vs. bypass surgery
An independent analysis of a clinical trial comparing the cost-effectiveness of the CYPHER® Sirolimus-eluting Coronary Stent vs. bypass surgery suggests that treatment with the CYPHER® Stent offers a potential cost-savings over bypass surgery. The findings from the Arterial Revascularization Therapy Study (ARTS) I and II were presented today at the annual Transcatheter Cardiovascular Therapeutics (TCT 2005) Conference. (2005-10-20)

Single-donor islet transplantation procedure shows promise for patients with type 1 diabetes
Patients with type 1 diabetes who received islet transplantation from a single donor pancreas were insulin independent one year later, according to a study in the February 16 issue of JAMA, a theme issue on medical applications of biotechnology. (2005-02-15)

Little-used drug combination may extend the lives of lung transplant patients
Median survival after lung transplant is less than six years. To see what might help lung transplant recipients live longer, University of Maryland School of Medicine researchers analyzed US lung transplant data, focused on immunosuppression regimes, and found a drug combination that appears to significantly extend patient survival. (2019-08-28)

CRF announces late breaking trials and first report investigations to be presented at TCT 2010
Transcatheter Cardiovascular Therapeutics is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss leading-edge developments in interventional cardiovascular medicine. Now in its 22nd year, it is the world's largest privately run medical conference and attended by more than 10,000 participants each year. TCT 2010 will be held Sept. 21-25 in Washington, D.C. (2010-08-05)

Rapamycin treatment prevents crippling abnormal bone formation after severe limb injuries
Individuals with severe injuries to their extremities often develop abnormal extra-skeletal bone in damaged or healing tissue, known as heterotopic ossification (HO). This post-traumatic abnormal wound healing can interfere with recovery, causing chronic pain, reduced mobility, and impaired prosthetic limb function. A new study describes a potential treatment breakthrough. Rapamycin, an FDA-approved drug already on the market, was found to dramatically reduce the presence of HO in rats, suggesting it has potential to become the first effective treatment to prevent HO. (2017-10-11)

What are risk factors for melanoma in kidney transplant recipients?
Kidney transplant patients appear to be at a greater risk of developing melanoma than the general population and risk factors include being older, male and white, findings that corroborate results demonstrated in other studies, according to a new article published by JAMA Dermatology. (2017-07-26)

Results with new bioresorbable stent (BRS) technologies reported at EuroPCR 2017
Paris, France: Promising results were reported in late-breaking trials with novel bioresorbable stent technologies at EuroPCR 2017, paving the way for ongoing developments in stents that are dissolved or reabsorbed after achieving vessel expansion in percutaneous coronary intervention procedures. (2017-05-19)

Inhibition of HDAC and mTOR may improve outcomes for relapsed/refractory Hodgkin lymphoma
The histone deacetylase (HDAC) inhibitor vorinostat (Zolinza) in combination with the mTOR inhibitor sirolimus (Rapamune) or everolimus (Afinitor) showed clinical efficacy in patients with relapsed/refractory Hodgkin lymphoma, according to results from a phase I clinical trial. (2020-10-14)

OHSU expert co-authors study finding treatment for rare lung disease
A new study has revealed a drug approved to prevent rejection in organ transplant patients helped treat a rare lung disease in women. (2011-04-11)

One year results from the REDUCE trial reported at TCT 2017
Results from the prospective, multicenter, randomized investigator-initiated REDUCE trial were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. (2017-11-01)

Sirolimus-eluting stent better than zotarolimus-eluting stent in everyday clinical practice
The widely used sirolimus-eluting stent is superior to the second-generation zotarolimus-eluting stent for patients in everyday clinical practice, concludes the SORT OUT III study published online first and in this week's edition of the Lancet. (2010-03-15)

A 'profound' success in treating children and young adults with rare blood disorders
Hematology researchers have safely and effectively treated children and young adults for autoimmune blood disorders in a multicenter clinical trial. In children with one of those conditions, autoimmune lymphoproliferative syndrome, all the patients showed a durable, complete response, with normal blood cell counts and rapid improvements, a result the study team called 'profound.' (2015-10-26)

New therapeutic combination to slow resistant sarcomas
Researchers at sarcomas research group at the Bellvitge Biomedical Research Institute and the Catalan Institute of Oncology have been tested in 19 patients a new therapeutic combination to combat resistant sarcomas. The clinical trial results, which indicate that the new treatment could stabilize the growth of these tumors have been published this week in the British Journal of Cancer. (2014-07-10)

Results from the BIO-RESORT trial presented at TCT 2016 and published in The Lancet
Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in treating an all-comers population with a high proportion of patients with acute coronary syndromes. (2016-10-30)

Page 1 of 4 | 145 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.